Verastem, Inc. (VSTM)

Verastem's stock experienced several events and fluctuations over the past six months. In November 2025, its market capitalization was approximately $610.7 million, with the stock priced at $9.81 per share, reflecting a 149.62% increase over the prior year. The company reported net product revenue of $11.2 million in Q3 2025. In February 2026, Verastem announced preliminary Q4 and full-year 2025 net product revenues, reporting approximately $17.5 million for Q4 and $30.9 million for the full year. On March 4, 2026, Verastem reported its full Q4 and full-year 2025 financial results. On May 7, 2026, Verastem reported Q1 2026 financial results, with net product revenue of $18.7 million. The stock price has shown volatility, with a 52-week range between $4.01 and $11.25. As of May 6, 2026, the share price was $6.01, representing a 10.16% decline over the past year. Shareholders have experienced substantial dilution, with a 91% increase in shares outstanding, and there has been significant insider selling.

Verastem, Inc. has experienced demand seasonality for its products and services, particularly impacting its AVMAPKI FAKZYNJA CO-PACK. During the first quarter of 2026, the company was affected by "seasonal headwinds" including insurance turnover, reverifications, and severe weather, which hindered patient access. Despite these challenges, the company observed a rebound in new patient numbers since January 2026. Verastem's management is focused on strategies to maintain demand for new patient starts, encourage earlier use of the therapy, and support patients in staying on treatment.

Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing novel small molecule drugs for RAS/MAPK pathway-driven cancers. The company operates in the Healthcare sector and Biotechnology industry, discovering, developing, and commercializing therapies targeting critical signaling pathways in cancer. Its major commercial product is AVMAPKI™ FAKZYNJA™ CO-PACK, approved by the FDA in May 2025 for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC). Verastem also has a pipeline of targeted therapies, including VS-7375, a potential oral KRAS G12D inhibitor. Historically, the company had COPIKTRA (duvelisib), an oral inhibitor approved in 2018 for certain leukemias and lymphomas, but later shifted its focus.

Verastem, Inc. is headquartered in Needham, Massachusetts, and incorporated in Delaware. Its primary commercialization efforts for AVMAPKI FAKZYNJA CO-PACK are in the U.S. Verastem is pursuing regulatory pathways for global expansion into Europe and Japan and is conducting the RAMP201J Phase 2 clinical trial in Japan.

Verastem's brand reputation has been influenced by its progress in clinical development and commercialization efforts. The company holds a "Moderate Buy" consensus rating from analysts, with an average rating score of 2.90. Positive events include data and regulatory updates from its RAMP-201 trial and the FDA's acceptance and priority review of the New Drug Application. Encouraging preliminary data from the Phase 1/2A trial of VS-7375 also bolstered its standing. The company has actively worked to raise awareness for its commercial product through initiatives like the HCP and Patient Reimagine Campaign and the launch of an LGSOC Resource Guide. Challenges include "seasonal headwinds" affecting patient access and early discontinuations, prompting management to make targeted changes to its commercial organization and leadership.

Verastem, Inc. is overwhelmingly controlled by institutional investors, who hold a significant majority of the company's outstanding shares. As of May 8, 2026, institutions held 88.37% of the stock. As of May 5, 2026, there were 147 institutional owners holding a total of 79,367,747 shares. Major institutional owners include Rtw Investments, Lp, Deep Track Capital, LP, BlackRock, Inc., Vanguard Group Inc, Polar Capital Holdings Plc, Armistice Capital, Llc, State Street Corp, Balyasny Asset Management Llc, Foresite Capital Management VI LLC, and Stonepine Capital Management, LLC. Insiders hold around 1.94% of the stock.